(3S,4S)-3-aminomethyl-1-benzyl-4-methylpyrrolidinecarbonitrile | 229323-09-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3S,4S)-3-aminomethyl-1-benzyl-4-methylpyrrolidinecarbonitrile
• 英文别名: cis-1-benzyl-4-methyl-3-aminomethylpyrrolidine；(3S,4S)-1-benzyl-4-methyl-3-aminomethylpyrrolidine；[(3S,4S)-1-benzyl-4-methylpyrrolidin-3-yl]methanamine
• CAS: 229323-09-5
• 化学式: C₁₃H₂₀N₂
• 分子量: 204.315
• InChiKey: GLFBPDDMMVIVQJ-YPMHNXCESA-N

物化性质

• 沸点：
  294.1±13.0 °C(Predicted)
• 密度：
  1.007±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-氨基-5-氯-2-甲氧基苯甲酸 、 (3S,4S)-3-aminomethyl-1-benzyl-4-methylpyrrolidinecarbonitrile 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 以80%的产率得到4-amino-N-[[(3R,4R)-1-benzyl-4-methylpyrrolidin-3-yl]methyl]-5-chloro-2-methoxybenzamide
  参考文献：
  名称：

  Development of Potent Serotonin-3 (5-HT3) Receptor Antagonists. I. Structure-Activity Relationships of 2-Alkoxy-4-amino-5-chlorobenzamide Derivatives.

  摘要：

  合成了一系列新的2-烷氧基-4-氨基-5-氯苯甲酰胺衍生物，这些衍生物在氨基部分包含五到七元的杂环非芳香环，并通过测试其对大鼠冯·贝佐尔德-雅里希反射的拮抗能力来评估其对血清素-3（5-HT3）受体的拮抗活性。五到七元的杂环包括吡咯烷、吗啉、1,4-噻嗪、哌啶、哌嗪、1,4-噁唑烯、1,4-噻唑烯、七元环及1,4-二唑烯环。其中，某些具有1,4-二唑烯环的苯甲酰胺衍生物表现出了强效的5-HT3受体拮抗活性。特别是4-氨基-5-氯-N-(1,4-二甲基六氢-1H-1,4-二唑啉-6-基)-2-乙氧基苯甲酰胺（96）和1-苄基-4-甲基六氢-1H-1,4-二唑啉类似物103展现了强效的5-HT3受体拮抗活性，而未表现出对5-HT4受体的结合亲和力。

  DOI：

  10.1248/cpb.43.1364
• 作为产物：
  描述：

  (3R,4S)-1-benzyl-4-methyl-3-pyrrolidinecarbonitrile 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 2.0h， 生成 (3S,4S)-3-aminomethyl-1-benzyl-4-methylpyrrolidinecarbonitrile
  参考文献：
  名称：

  由天冬氨酸合成的N-（3-吡咯烷基甲基）苯甲酰胺的对映体和非对映体控制的多巴胺D1，D2，D3和D4受体结合。

  摘要：

  描述了N-（3-吡咯烷基）苯甲酰胺的亚受体选择性调节，导致选择性的多巴胺D3配体ent1h以及优选分别识别人D2或D4受体的衍生物1g和1e / ent1e。结合概况由绝对和相对构型两者控制。对映体纯的目标化合物由天冬氨酸合成。

  DOI：

  10.1016/s0960-894x(99)00086-4

文献信息

• Enantio- and diastereocontrolled dopamine D1, D2, D3 and D4 receptor binding of N-(3-pyrrolidinylmethyl)benzamides synthesized from aspartic acid
  作者：Christoph Thomas、Harald Hübner、Peter Gmeiner

  DOI：10.1016/s0960-894x(99)00086-4

  日期：1999.3

  N-(3-pyrrolidinyl)benzamides leading to the selective dopamine D3 ligand ent1h and the derivatives 1g and 1e/ent1e which preferably recognize human D2 or D4 receptors, respectively, is described. Binding profiles were controlled by both, absolute and relative configuration. The enantiopure target compounds were synthesized from aspartic acid.

  描述了N-（3-吡咯烷基）苯甲酰胺的亚受体选择性调节，导致选择性的多巴胺D3配体ent1h以及优选分别识别人D2或D4受体的衍生物1g和1e / ent1e。结合概况由绝对和相对构型两者控制。对映体纯的目标化合物由天冬氨酸合成。
• 10-(3-cyclopropylaminomethyl-1-pyrrolidinyl)pyridobenzoxazinecarboxylic acid derivative effective against resistant bacterium
  申请人：Asahina Yoshikazu

  公开号：US20050182052A1

  公开（公告）日：2005-08-18

  A compound as represented by the general formula (I) shown below exhibits high antibacterial activity against gram-positive bacteria, in particular, such drug-resistant bacteria as mRNA, PRSP and VRE: wherein R1 is a methyl group, a fluoromethyl group, a methoxymethyl group, an acetoxymethyl group, a hydroxymethyl group or a methylene; R2 is a hydrogen atom, a lower alkyl group having 1 to 3 carbon atoms, or a pharmaceutically acceptable cation and an ester of a prodrug; R3 is a hydrogen atom or a halogen atom; R4 is a hydrogen atom, a lower alkyl group having 1 to 3 carbon atoms, a fluoromethyl group, a trifluoromethyl group or a fluorine atom; and R5 is a hydrogen atom or a fluorine atom, with exceptions where R1 is a methyl group, R4 and R5 are at the same time a hydrogen atom, and R3 is a fluorine atom.

  下列通式（I）所代表的化合物对革兰氏阳性细菌表现出高度的抗菌活性，特别是对那些耐药菌如mRNA、PRSP和VRE： 其中，R1是甲基、氟甲基、甲氧甲基、乙酰氧甲基、羟甲基或亚甲基；R2是氢原子、具有1至3个碳原子的低烷基或药学上可接受的阳离子和前药的酯；R3是氢原子或卤素原子；R4是氢原子、具有1至3个碳原子的低烷基、氟甲基、三氟甲基或氟原子；R5是氢原子或氟原子，除非R1是甲基、R4和R5同时为氢原子，且R3是氟原子的情况。
• 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative
  申请人：Asahina Yoshikazu

  公开号：US20060281779A1

  公开（公告）日：2006-12-14

  OBJECT To provide novel quinolonecarboxylic acid compounds serving as safe, strong antibacterial agents that are effective against drug-resistant bacteria that are less susceptible to conventional antibacterial agents. SOLVING MEANS There are provided 7-(4-substituted-3-cyclopropylaminomethylpyrrolidinyl)quinolonecarboxylic acid derivatives (such as 1-cyclopropyl-7-[(3S,4S)-3-cyclopropylaminomethyl-4-fluoro-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid) that exhibit strong antibacterial activity against gram-positive bacteria, such as MRSA, PRSP and VRE, while being safe. The compounds are shown by the following general formula (I):

  目的：提供新型喹诺酮羧酸化合物，作为安全、强效的抗菌剂，对耐药菌有良好的抗菌效果，而且对传统抗菌剂的抗性较低。 解决方法：提供7-(4-取代的3-环丙氨甲基吡咯烷基)喹诺酮羧酸衍生物（例如1-环丙基-7-[(3S,4S)-3-环丙氨甲基-4-氟-1-吡咯烷基]-6-氟-1,4-二氢-8-甲氧基-4-氧代-3-喹啉羧酸），对革兰氏阳性菌（如MRSA、PRSP和VRE）表现出强效的抗菌活性，同时具有安全性。这些化合物的通用式如下（I）：
• 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative technical field
  申请人：Asahina Yoshikazu

  公开号：US20090176824A1

  公开（公告）日：2009-07-09

  Object To provide novel quinolonecarboxylic acid compounds serving as safe, strong antibacterial agents that are effective against drug-resistant bacteria that are less susceptible to conventional antibacterial agents. Solving Means There are provided 7-(4-substituted-3-cyclopropylaminomethylpyrrolidinyl)quinolonecarboxylic acid derivatives (such as 1-cyclopropyl-7-[(3S,4S)-3-cyclopropylaminomethyl-4-fluoro-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid) that exhibit strong antibacterial activity against gram-positive bacteria, such as MRSA, PRSP and VRE, while being safe. The compounds are shown by the following general formula (I):

  目标 提供新型喹诺酸类化合物，作为安全、强效的抗菌剂，对耐药菌有良好的抗菌效果，对传统抗菌剂不敏感。 解决方法 提供7-(4-取代-3-环丙氨甲基吡咯烷基)喹诺酸衍生物（如1-环丙基-7-[(3S,4S)-3-环丙氨甲基-4-氟-1-吡咯烷基]-6-氟-1,4-二氢-8-甲氧基-4-氧代-3-喹啉羧酸），对革兰阳性菌有强效的抗菌活性，如MRSA、PRSP和VRE，同时具有安全性。这些化合物的一般式如下（I）：
• 10-(3-CYCLOPROPYLAMINOMETHYL-1-PYRROLIDINYL)PYRIDOBENZOXAZINECARBOXYLIC ACID DERIVATIVE EFFECTIVE AGAINST RESISTANT BACTERIUM
  申请人：Kyorin Pharmaceutical Co., Ltd.

  公开号：EP1486500A1

  公开（公告）日：2004-12-15

  A compound as represented by the general formula (I) shown below exhibits high antibacterial activity against gram-positive bacteria, in particular, such drug-resistant bacteria as MRNA, PRSP and VRE: wherein R1 is a methyl group, a fluoromethyl group, a methoxymethyl group, an acetoxymethyl group, a hydroxymethyl group or a methylene; R2 is a hydrogen atom, a lower alkyl group having 1 to 3 carbon atoms, or a pharmaceutically acceptable cation and an ester of a prodrug; R3 is a hydrogen atom or a halogen atom; R4 is a hydrogen atom, a lower alkyl group having 1 to 3 carbon atoms, a fluoromethyl group, a trifluoromethyl group or a fluorine atom; and R5 is a hydrogen atom or a fluorine atom, with exceptions where R1 is a methyl group, R4 and R5 are at the same time a hydrogen atom, and R3 is a fluorine atom.

  下图所示通式(I)代表的化合物对革兰氏阳性菌，特别是 MRNA、PRSP 和 VRE 等耐药菌具有很强的抗菌活性： 其中 R1 是甲基、氟甲基、甲氧基甲基、乙酰氧甲基、羟甲基或亚甲基；R2 是氢原子、具有 1 至 3 个碳原子的低级烷基或药学上可接受的阳离子和原药的酯类；R3 是氢原子或卤素原子；R4 是氢原子、1-3 个碳原子的低级烷基、氟甲基、三氟甲基或氟原子；R5 是氢原子或氟原子，但 R1 是甲基、R4 和 R5 同时是氢原子和 R3 是氟原子的情况除外。